Equity Research, Broker Reports, and media content on ANGLE plc

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about ANGLE plc
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard
  • 28 Apr 22
Trinity Delta Lighthouse: ANGLE

Trinity Delta view: During 2021 ANGLE laid important foundations ahead of key events that should accelerate commercial prospects. Positive momentum in pharma services contracts and corporate partnerships coupled to new assay and LDT development will contribute to top-line growth. However, potential FDA clearance of the Parsortix system in mBC is a clear focus for many investors and will provide important validation for external partners. ANGLE is well positioned to capitalise on growing recognit

Companies: ANGLE plc
  • 25 Mar 22
Hybridan Small Cap Feast 25/03/22

Joiners: Beacon Rise Holdings (BRS.L) joins the Main Market. The Company was formed to undertake acquisitions of UK or EU businesses or assets with operations in the primary and secondary segment of the education technology sector. The Company does not have any specific acquisitions under consideration at present and does not expect to engage in substantive negotiations with any target business or asset until after Admission. Leavers: No Leavers Today. What’s cooking in the IPO kitchen? Asimilar

Companies: AGL BOKU BMN CYAN EME JNEO MAI SNT TMT

  • 15 Mar 22
Hybridan Small Cap Feast 14/03/22

Joiners: CYBA (CYBA.L) has completed the reverse takeover of Narf Industries on the Main Market (Standard), a US based group with a track record of successful and advanced cyber security projects with the US Department of Defense and affiliated government agencies like the Defense Advanced Research Projects Agency. £6m raised. Leavers: No leavers today. What’s cooking in the IPO kitchen? Aquis Exchange (AQX.L) the exchange services group, announced its intention to apply for admission of the Gro

Companies: ROL CIN OHG PCIP AGL AGM BZT GATC

  • 21 Jan 22
Hybridan Small Cap Feast 21/01/2022

Joiners: No Joiners Today. Leavers: No Leavers Today. What’s cooking in the IPO kitchen? Hercules Site Services a technology enabled labour supply company for the UK infrastructure sector, intends to float on AIM. Hercules is seeking to raise approximately £5.5m to rapidly deliver on the significant demand it is experiencing for its diverse range of services across the UK infrastructure sector, including to scale up its operations to supply labour to the northern section of the HS2 rail project

Companies: WSG ADME AGL CCT EMAN OHG OTMP TLY

  • 17 Jan 22
FDA approval awaited, LDT data expected H122

ANGLE’s updates reveal dialogue with FDA for Parsortix’s approval for use in mBC (metastatic breast cancer) is continuing and constructive, first submissions for accreditation of UK and US clinical laboratories have been made, but development of the ovarian cancer LDT (Laboratory Developed Test) has been hampered by a delay to data read out from a key study (due to third-party supply issues) to H122. A new study comparing CTC harvest and downstream analysis against biopsies in mBC shows good cor

Companies: ANGLE plc
  • 15 Nov 21
Small Cap Feast 15/11/2021

Banquet Buffet ADM Energy* 1.7p £2.7m (ADME.L) Fundraise and Issue of Equity to Raise £475,000 at 1.5p and Business Update by the natural resources investing company. Conditional Issue of 6,666,667 warrants with an exercise price of 3p each for a period of two years from Admission.  Subscriptions by five Directors amounting to £175,000 at the placing price.  Additional conversion by debt holders, consultants and service providers equating to £228,500 at the placing price. The funds will be used

Companies: SHED AGL ADME AAU KIBO MKA ORPH SEE SGI

  • 01 Oct 21
Poised to disrupt existing tumour assay protocols

ANGLE’s H121 results confirm progress of its proprietary Parsortix cancer diagnostic platform across multiple fronts. Whilst attention inevitably focusses on the expected upcoming FDA approval for use in metastatic breast cancer, important progress has been achieved with developing the ovarian cancer LDT (Laboratory Developed Test). UK and US clinical laboratories, created ahead of schedule, are anticipated to receive certification by year-end. This will drive nearer term revenues from pharma se

Companies: ANGLE plc
  • 28 Jul 21
FTSE lacks direction, US tech giants report thumping results as traders nervously await US Fed update
ftse-lacks-direction-us-tech-giants-report-thumping-results-as-traders-nervously-await-us-fed-update
  • 28 Jul 21
Small Cap Feast: 28/07/21

Joiners: Big Technologies (BIG.L) has joined AIM. Big Technologies plc provides products and services to the remote and personal monitoring industry under a number of brand and trading names, with 'Buddi' being the most well known and used in respect of activities within the core criminal justice market. The Company's criminal justice solution involves proprietary monitoring software combined with modular monitoring hardware being used to accurately track the location of tag wearers. Alongside

Companies: AGL CMCL CEG CCS EEE GOOD PPC SMS TRCS ZPHR

  • 28 Jun 21
£20m placing to accelerate Parsortix opportunities

ANGLE has raised £20m (gross) to maintain momentum in consolidating its position as the leading player in CTC liquid biopsy. Its proprietary Parsortix microfluidic device captures circulating tumour cells (CTCs) for analysis and can complement ctDNA (circulating tumour DNA) liquid biopsies. New monies boost pro forma cash to c £47m supporting current initiatives (eg breast and ovarian cancer), new opportunities to expand Parsortix’s utility, and expanding the commercial infrastructure. ANGLE has

Companies: ANGLE plc
  • 25 Jun 21
Small Cap Feast: 25/06/21

What’s cooking in the IPO kitchen? Seraphim Space Investment Trust PLC, a newly established closed-ended investment company which will invest in a diversified international portfolio of early and growth stage Space Tech businesses, announces the publication of its Prospectus in connection with the IPO to the Premium Segment of the Main Market. The Company is targeting gross proceeds of up to £180m through the issue of up to 180m Ordinary Shares by way of the Initial Placing, the Offer for Subsc

Companies: ANA AGL DEC JADE MMH MIRI MJH SHNJ RUA SML

  • 21 May 21
Angle (LON:AGL) Presenting at the Proactive One2One Virtual Forum
angle-lon-agl-presenting-at-the-proactive-one2one-virtual-forum
  • 11 May 21
Parsortix commercial traction would be transformational

ANGLE is progressing its proprietary Parsortix cancer diagnostic platform through several key inflection points over the next 24 months, most notably FDA approval. In parallel, it has initiated commercialisation through the creation of two clinical laboratories (in the UK and US), which can offer services to the pharma industry and LDTs (Laboratory Developed Tests) for the clinical market. Parsortix is an elegant microfluidic device that captures circulating tumour cells (CTCs) for analysis. Suc

Companies: ANGLE plc
  • 16 Apr 21
ANGLE announce first large-scale pharma services contract for Parsortix liquid biopsy
angle-announce-first-large-scale-pharma-services-contract-for-parsortix-liquid-biopsy
  • 16 Apr 21
Small Cap Feast

Semper Fortis Esports* recently announced its intention to IPO onto the Access Segment of the Aquis Stock Exchange Growth Market. Semper is a multi-operational Esports organisation focusing on gaming technology solutions, brand enhancement and high growth team infrastructures. The company plans to raise £2.5m to develop their three core areas of establishing an esports team, forming partnerships with brands for sponsorship and B2B consultancy services. The Board are highly experienced in spor

Companies: GAL AXS IDH GWMO AGL YEW HARL HE1 PPC CASP

ANGLE plc

Company Profile

  • Personnel
  • Andrew D Newland, CEO
  • Ian F Griffiths, Finance Director
  • Garth Selvey, Chairman

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on ANGLE plc. We currently have 60 research reports from 5 professional analysts.

Latest News/RNS

(more news)
Date Source Announcement
20May22 07:00 RNS Angle PLC - Prostate Cancer UK funds new study using Parsortix
28Apr22 07:00 RNS Angle PLC - Preliminary Results
20Apr22 07:00 RNS Angle PLC - Notice of Preliminary Results and Webcast
14Apr22 07:00 RNS Angle PLC - Poster on Parsortix system presented at AACR 2022
01Apr22 07:00 RNS Angle PLC - Identifying drug targets in cancer metastasis
29Mar22 07:00 RNS Angle PLC - Rapid information on patient response to therapies
25Mar22 07:00 RNS Angle PLC - Identifying therapeutic targets in TNBC patients
Get free RNS email alerts

  • Frequency of research reports

     

  • Research reports on

    ANGLE plc

  • Providers covering

    ANGLE plc

  • 17 May 22
First clinical evidence for LBP in asthma

MRx-4DP0004 is 4D Pharma’s oral, immunomodulatory, single strain Live Biotherapeutic product (LBP). The safety portion of this Phase 1/2 (Part A) met the primary endpoint of safety and tolerability, with five secondary endpoints qualitatively improved over the placebo arm. The data is being presented in poster session at the ATS meeting May 15-18, 2022.

Companies: 4d Pharma PLC
  • 17 May 22
Confidence in profitable expansion rebuilding

2021 was a tough year which saw the non-repeat of highly profitable hand sanitiser sales, almost no Chinese sales and the impact of input/cost inflation. However, it successfully integrated 2 acquisitions, which enhance the portfolio and earnings quality, and locked in the planned synergies. With new distribution agreements (inc to China), and mitigations in place to claw back lost margin, VLG looks set to return to profitable growth. The platform is highly scalable and trades on just 5x EV/EBIT

Companies: Venture Life Group Plc
  • 17 May 22
Bugs as drugs...and vaccines

4D Pharma is a pharmaceutical company developing Live Biotherapeutic Products (LBPs), a novel class of drug derived from the human gut microbiome. This differentiated approach focuses on leveraging the interactions of LBPs with host biology, underpinned by a proprietary MicroRx® platform. This has generated a strong clinical and preclinical pipeline of single strain LBPs targeting major diseases across multiple therapeutic area. A well flagged cash requirement overshadows the stock but the exper

Companies: 4d Pharma PLC
  • 06 May 22
Morning Note – 6 May 2022


Companies: SDI Group plc
  • 16 May 22
Morning Note – 16 May 2022


Companies: Kromek Group Plc (KMK:LON)Synairgen plc (SNG:LON)
  • 20 May 22
Cenkos: Healthcare Sector - Ward Round

Weekly round-up of AIM-listed healthcare news. Venture Life Group, GENinCode, Kromek, Alliance Pharma, Polarean Imaging, Benchmark Holdings, Ondine Biomedical, Verici Dx, Faron Pharmaceuticals, Avacta Group, Abingdon Health, Open Orphan, Belluscura, Hutchmed (China), Oxford Biodynamics

Companies: ANIC RUA CREO GENI HEIQ IHC IXI IUG OPTI SBTX VAL VLG

  • 16 May 22
CMD demonstrated broader opportunity set

Yourgene’s Capital Markets Day on 26/4 provided a strong illustration of the significant strategic progress the group has made in recent years. The pandemic was both a blessing and a curse for YGEN, delaying some opportunities, but catalysing others and leaving the group in a stronger net position than where it started. The building blocks are now in place and, as healthcare markets normalise globally, we believe Yourgene is poised for a period of extended growth, with multiple opportunities to

Companies: Yourgene Health Plc
  • 13 May 22
Cenkos: Healthcare Sector -- Ward Round

Weekly round-up of AIM-listed healthcare news. Agronomics, Eden Research, IXICO, HeiQ, Trellus Health, NetScientific, Circassia, 4basebio, Fusion Antibodies, Surgical Innovations Group, Yourgene Health, Abingdon Health, Verici Dx, Poolbeg Pharma, Omega Diagnostics

Companies: ANIC RUA CREO GENI HEIQ IHC IXI IUG OPTI SBTX VAL VLG

  • 16 May 22
Hybridan Small Cap Feast 16/05/22

Dish of the day Joiners: No Joiners Today. Leavers: No Leavers Today. What’s cooking in the IPO kitchen? Lekoil, the oil and gas exploration and production Company with a focus on Nigeria and West Africa intends to join the AQSE Growth Market. The Company was previously listed on AIM (LEK.L), however, Ordinary Shares have been suspended from trading on AIM since October 2021. Due 18th May 2022. EnSilica, intends to join AIM. EnSilica is a designer and supplier of mixed signal Application Specifi

Companies: EEE FARN FCAP HZM JLP NSCI SRE

  • 12 May 22
Continued growth and margin improvement prompt further upgrades

A positive AGM update confirms strong revenue growth has continued YTD and further margin improvement means management again expect EBITDA to be materially ahead of expectations. The business model is now settled, with additional distributors appointed in the US which should help drive further penetration into the Primary Care market there. China revenues were strong and with no sign yet of any slowdown, despite being cognisant of renewed lockdowns there. Gross margins have remained robust on po

Companies: Circassia Group PLC
  • 17 May 22
Cenkos: Venture Life Group Plc -- FY21 results, positive outlook

Venture Life Group has reported its results for FY21A, with revenues and adjusted EBITDA coming in ahead of our forecasts. Revenues, supported by two acquisitions, grew 9% to £32.8m with the acquisitions more than offsetting lost FY20A COVID-related sales and significantly reduced shipments to China. The gross margin was also affected by these factors, though also supported by higher margin acquisitions. Adjusted EBITDA grew 8%. Management have provided a positive outlook for FY22E, based on tra

Companies: Venture Life Group Plc
  • 19 May 22
SHORE CAPITAL - RUA Life Sciences - Cessation of coverage RYA, 42p - We are withdrawing our forecasts and ceasing research coverage


Companies: RUA Life Sciences Plc
  • 06 May 22
Omega Diagnostics - Placing raises £2.0m with Open Offer up to £2.0m

Omega Diagnostics has raised £2.0m, with up to £2.0m possible via an Open Offer to provide a bridge to the sale of the CD4 business and enable it to focus on the growth opportunities within its core business, Health & Nutrition. Having sold its Alva site in March for £1m, with a transitionary agreement put in place with Accubio until December 2022 to ensure the continued production of CD4 lateral flow tests, Omega has elected to sell the CD4 business, which would cost c.£1.5m to relocate to Ely

Companies: Omega Diagnostics Group PLC
  • 02 May 22
Farxiga + COVID-19 vaccine drives a strong Q1

Astra kicked-off 2022 on a good note, with solid growth in Farxiga and higher COVID-19 vaccine sales, off-setting weaknesses in lynchpin oncology and rare diseases. Although vaccine-driven top-line tailwinds are expected to dissipate soon, this is expected to be offset by a recovery in the core areas. In Q1, profitability again came under pressure but improved sequentially, and should improve further as the ‘young’ portfolio rolls over. Overall, decent results and our positive recommendation on

Companies: AstraZeneca PLC
  • 19 May 22
Poised for multiple value inflection points

FY21 results were well-trailed and contain no surprises. The company continues to execute in line or ahead of plan and, following a £10m fundraise post-period end, is funded through a number of key inflection points. Investors can look forward to a number of these in the near term, including commercial launch and first revenues from first product Tuteva later this year. Rolling forward our risk-adjusted DCF results in a further increase in our TP to 76p (from 65p). we reiterate our Buy recommend

Companies: Verici Dx Plc